• Please log in or register to access this feature.
You have free access to this content

An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder

  1. Michihiro Takahashi MD, PhD1,2,*,
  2. Yasushi Takita MS1,
  3. Taro Goto MD, PhD1,
  4. Hironobu Ichikawa MD, PhD3,
  5. Kazuhiko Saito MD, PhD4,
  6. Hideo Matsumoto MD, PhD5,
  7. Yasuo Tanaka MD6

Article first published online: 26 JAN 2011

DOI: 10.1111/j.1440-1819.2010.02159.x

Issue

Psychiatry and Clinical Neurosciences

Psychiatry and Clinical Neurosciences

Volume 65, Issue 1, pages 55–63, February 2011

Additional Information

How to Cite

Takahashi, M., Takita, Y., Goto, T., Ichikawa, H., Saito, K., Matsumoto, H. and Tanaka, Y. (2011), An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. Psychiatry and Clinical Neurosciences, 65: 55–63. doi: 10.1111/j.1440-1819.2010.02159.x

Author Information

  1. 1

    Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Kobe

  2. 2

    Terauchi-Takahashi Psychiatric Clinic, Ashiya

  3. 3

    Tokyo Metropolitan Children's Medical Center, Tokyo

  4. 4

    Department of Psychiatry & Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa

  5. 5

    Course of Specialized Clinical Science (Psychiatry), Tokai University School of Medicine, Isehara

  6. 6

    Research and Clinical Center for Child Development, Faculty of Education, Hokkaido University, Sapporo, Japan

* Michihiro Takahashi, Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Sannomiya Plaza Bldg., 7-1-5, Isogamidori, Chuo-ku, Kobe 651-0086, Japan. Email: takahashi_michihiro@lilly.com

Publication History

  1. Issue published online: 26 JAN 2011
  2. Article first published online: 26 JAN 2011
  3. Received 29 October 2009; revised 15 September 2010; accepted 14 October 2010.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (263K)

REFERENCES

  • 1
    Adler LA, Chua HC. Management of ADHD in adults. J. Clin. Psychiatry 2002; 63 (Suppl 12): 29–33.
  • 2
    Barkley RA. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 2nd edn. Guilford Press, New York, 1998.
  • 3
    Biederman J, Petty C, Fried R et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 2006; 163: 1730–1738.
  • 4
    Weiss G, Hechtman LT. Hyperactive Children Grown Up: ADHD in Children, Adolescents, and Adults. Guilford Press, New York, 1993.
  • 5
    Faraone SV, Biederman J, Spencer T et al. Attention-deficit/hyperactivity disorder in adults: An overview. Biol. Psychiatry 2000; 48: 9–20.
  • 6
    Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr. Clin. North. Am. 2004; 7: 187–201.
  • 7
    Tanaka Y. Attention-deficit hyperactivity disorder in adulthood: the current state and problems. J. Psychiatr. Treat. 2004; 19: 415–424.
  • 8
    Montano B. Diagnosis and treatment of ADHD in adults in primary care. J. Clin. Psychiatry 2004; 65: 18–21.
  • 9
    Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699–711.
  • 10
    Heil SH, Holmes HW, Bickel WK et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002; 67: 149–156.
  • 11
    Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab. Dispos. 2002; 30: 319–323.
  • 12
    Sauer JM, Ponsler GD, Mattiuz EL et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab. Dispos. 2003; 31: 98–107.
  • 13
    Shimizu T, Ochiai H, Asell F et al. Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab. Pharmacokinet. 2003; 18: 48–70.
  • 14
    Takahashi M, Takita Y, Yamazaki K et al. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2009; 19: 341–350.
  • 15
    Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol. Psychiatry 2003; 53: 112–120.
  • 16
    Spencer T, Biederman J, Wilens T et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 1998; 155: 693–695.
  • 17
    Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). Multi-Health Systems Inc, North Tonawanda, 1999.
  • 18
    Takahashi M, Takita Y, Ichikawa H et al. Reliability and validity of the Japanese version of CAARS-Screening version (CAARS-SV), Adult ADHD symptom rating scale. Clin. Psychiatry 2011; 53: 23–34.
  • 19
    Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare, Bethesda, MD, 1976.
  • 20
    National Institute of Mental Health. Clinical global impression scale. Psychopharmacol. Bull. 1985; 21: 839–943.
  • 21
    Adler L, Dietrich A, Reimherr FW et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann. Clin. Psychiatry 2006; 18: 107–113.
  • 22
    Adler LA, Spencer T, Brown TE et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J. Clin. Psychopharmacol. 2009; 29: 44–50.
View Full Article (HTML) Get PDF (263K)